e8vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 8, 2003

King Pharmaceuticals,Inc.
(Exact name of registrant as specified in its charter)

         
Tennessee
(State or other jurisdiction
of incorporation)		   0—24425
(Commission
File Number) 		  54-1684963
(IRS Employer
Identification Number)
     
501 Fifth Street, Bristol, Tennessee
(Address of principal executive offices)		   37620
(Zip Code)

Registrant’s telephone number, including area code: 423-989-8000

Not Applicable
(Former name or former address, if changed since last report)

 

TABLE OF CONTENTS

SIGNATURE
Exhibit Index
PRESS RELEASE
PRESS RELEASE

Table of Contents

Item 5. Other Events

     Effective January 8, 2003, King Pharmaceuticals, Inc., a Tennessee corporation, merged with Meridian Medical Technologies, Inc. The transaction was previously announced. Under the terms of the agreement, Meridian shareholders will receive a cash payment of $44.50 for each share of Meridian common stock held of record on January 8, 2003. On January 8 and January 9, 2003, King issued press releases regarding, respectively, the approval of the transaction by shareholders of Meridian and the closing of the transaction.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

     (a)  Financial Statements on Businesses Acquired.

       None.

     (b)  Pro Forma Financial Information.

       None.

     (c)  Exhibits.

       The following exhibits are filed pursuant to Item 601 of Regulation S-K:

Exhibits:

                 
Exhibit                
Number   Description of Exhibit        
 
       
99.1
   Press Release of King Pharmaceuticals, Inc. dated January 8, 2003.
 
    
99.2
   Press Release of King Pharmaceuticals, Inc. dated January 9, 2003.

 

Table of Contents

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     Date: January 9, 2003

  KING PHARMACEUTICALS, INC.

  By: /s/ James R. Lattanzi
James R. Lattanzi
Chief Financial Officer

 

Table of Contents

Exhibit Index

                 
Exhibit                
Number   Description of Exhibit        
 
       
99.1
   Press Release of King Pharmaceuticals, Inc. dated January 8, 2003.
 
    
99.2
   Press Release of King Pharmaceuticals, Inc. dated January 9, 2003.